Medication-Related Osteonecrosis of the Jaw Subsequent to Periimplantitis: A Case Report and Literature Review

2020 ◽  
Author(s):  
Keisuke Seki ◽  
Shunsuke Namaki ◽  
Atsushi Kamimoto ◽  
Yoshiyuki Hagiwara
Keyword(s):  
Literature Review ◽  
Medical Condition ◽  
Postoperative Recurrence ◽  
Osteonecrosis Of The Jaw ◽  
Treatment Of Osteoporosis ◽  
Oral Bisphosphonate ◽  
Osseointegrated Implants ◽  
Dental Hospital ◽  
Molar Region

Abstract The aim of this report was to document a rare case of medication-related osteonecrosis of the jaw (MRONJ) that developed around the already osseointegrated implants in the maxillary right molar region. A 73-year-old woman presented at our university dental hospital in May 2017 with a chief complaint of discomfort near a maxillary implant. During the implant maintenance period, the patient began taking alendronate sodium hydrate (Fosamac ® tablets 35 mg once weekly), an oral bisphosphonate (BP), for treatment of osteoporosis. Eight years after starting implant maintenance, peri-implantitis occurred, for which mechanical cleaning and antimicrobial therapy was performed. Peri-implantitis symptoms disappeared, and the medical condition improved. However, MRONJ developed 4 years after she commenced taking the BP. The patient underwent implant removal and sequestrectomy. There was no postoperative recurrence. The events this patient experienced imply that a local infection around an implant and type 1 diabetes are factors in MRONJ development. It is important to note that implants in patients taking BPs should be more carefully maintained. In addition, we performed literature review and discovered only a few similar cases.

scholarly journals Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate

2021 ◽  
Vol 11 ◽  
Author(s):  
Marília A. Figueiredo ◽  
Frederico Buhatem Medeiros ◽  
Karem López Ortega
Keyword(s):  
Osteonecrosis Of The Jaw ◽  
Treatment Of Osteoporosis ◽  
Oral Bisphosphonate

scholarly journals Oral Bisphosphonate Related Osteonecrosis of the Jaw: A Challenging Adverse Effect

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Ilke Coskun Benlidayi ◽  
Rengin Guzel
Keyword(s):  
Risk Factors ◽  
Adverse Effect ◽  
Current Knowledge ◽  
Osteonecrosis Of The Jaw ◽  
Oral Bisphosphonates ◽  
Treatment Of Osteoporosis ◽  
Preventative Measures ◽  
Oral Bisphosphonate ◽  
Surgical Methods ◽  
Antiresorptive Drugs

Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw (BRONJ). With a better understanding of this side effect, reported incidences for BRONJ in oral bisphosphonate users have increased in time. The pathogenesis of BRONJ has not been well determined. Several risk factors such as dentoalveolar surgery, therapy duration, and concomitant steroid usage have been linked to BRONJ. Conservative and surgical methods can be preferred in the treatment. Preventative measures are of great importance for the patients at high risk. In this paper, osteonecrosis of the jaw secondary to oral bisphosphonates was reviewed in order to increase awareness as well as to renew the current knowledge.

scholarly journals Oral bisphosphonate induced osteonecrosis of the jaw causing pathological mandibular fracture: literature review and a case report

2016 ◽  
Vol 12 (1) ◽  
pp. 57-63
Author(s):  
Gonca Duygu Çapar ◽  
Gül Merve Yalçın Ülker ◽  
Fatih Cabbar ◽  
Ceyda Özçakır Tomruk
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Osteonecrosis Of The Jaw ◽  
Mandibular Fracture ◽  
Oral Bisphosphonate

Oral Bisphosphonate–Associated Osteonecrosis of the Jaw After Implant Surgery: A Case Report and Literature Review

2010 ◽  
Vol 68 (7) ◽  
pp. 1662-1666 ◽  
Author(s):  
Alberto Bedogni ◽  
Giordana Bettini ◽  
Andrea Totola ◽  
Giorgia Saia ◽  
Pier Francesco Nocini
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Osteonecrosis Of The Jaw ◽  
Implant Surgery ◽  
Oral Bisphosphonate

scholarly journals Drug-induced jaw osteonecrosis

Ozone Therapy ◽  
2019 ◽  
Vol 4 (3) ◽  
pp. 48-54
Author(s):  
Girolamo Donati
Keyword(s):  
Osteonecrosis Of The Jaw ◽  
Ozone Therapy ◽  
Drug Induced ◽  
Treatment Of Osteoporosis ◽  
Oral Bisphosphonate ◽  
Tissue Healing ◽  
Biological Target ◽  
Infection And Inflammation ◽  
Antiangiogenic Drugs ◽  
Efficient Alternative

Medication-related osteonecrosis of the jaw (MRONJ), an adverse reaction to medication, has been reported since 2002, at first in cancer patients with bone metastases treated intravenously with pamidronate or zoledronate, and later in patients taking oral bisphosphonate for the treatment of osteoporosis. Several cases of MRONJ have also been described in patients treated with antiangiogenic drugs with a so-called biological target (bevacizumab, sunitinib, sorafenib). Oxygen/ozone therapy for MRONJ treatment represents a possible and efficient alternative to the two main therapeutic approaches currently in use, antibiotic therapy and surgery. Since 2010, I have diagnosed 51 MRONJ cases at ASST Fatebenefratelli-Sacco. Subsequently and following the approval of the Ethics Committee (2015), patients with MRONJ level 1 and 2 have been included in an experimental protocol with oxygen/ozone therapy: Treatment of bisphosphonate-related osteonecrosis of the jaw with oxygen/ozone therapy and surgical debridement with piezoelectric scalpel. The study is currently running and up to now six out of fourteen patients healed perfectly. Among these six, four spontaneously or almost spontaneously have expelled the necrotic part without undergoing surgery. In three cases, there was only an improvement in symptoms. Five patients are currently being treated. Because of its antiseptic properties, oxygen ozone therapy reduced the effects of infection and inflammation, while the bio stimulant action of this therapy promoted the demarcation of bone sequestration and soft tissue healing.

Use of diluted insulin in the management of very young children with type 1 diabetes: case report and literature review

2018 ◽  
Author(s):  
A Emile J Hendriks ◽  
Ross L Ewen ◽  
Yoke Sin Hoh ◽  
Nazia Bhatti ◽  
Rachel M Williams ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Case Report ◽  
Young Children ◽  
Literature Review ◽  
Diabetes Case ◽  
Very Young Children

The Prevalence of Vitamin D Deficiency in Iran: A Literature Review

2020 ◽  
Vol 16 (7) ◽  
pp. 1015-1027
Author(s):  
Mohammad Bagherniya ◽  
Zahra Khorasanchi ◽  
Mina S. Bidokhti ◽  
Gordon A. Ferns ◽  
Mitra Rezaei ◽  
...  
Keyword(s):  
Vitamin D ◽  
Literature Review ◽  
Vitamin D Deficiency ◽  
Medical Condition ◽  
Scientific Information ◽  
Age Groups ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Vitamin D Levels ◽  
High Prevalence

Background: Vitamin D deficiency is a common medical condition worldwide. In Iran, it has been reported that between 30-90% of people have vitamin D deficiency. However, its distribution in different parts of the country and among different age and regional groups is unclear. Therefore, the aim of this study was to review the recent literature on vitamin D deficiency in Iran. Methods: The literature review was performed using Web of Science, PubMed-Medline, Scopus and Scientific Information Database (SID) with a cut-off date of November 2016 to identify articles on vitamin D status in Iran published in the last 10 years. Studies in English and Persian that reported vitamin D levels in male and female subjects of all age groups and in healthy populations were included. Results: From 325 studies that were initially retrieved, 82 articles met the inclusion criteria. A high prevalence of vitamin D deficiency was reported, and in some regions, this was reported as >90% and was found in all age groups and in all regions of Iran. Conclusion: This review highlights the very high prevalence of vitamin D deficiency in Iran. It will be important to recognize the importance of vitamin D deficiency as a major public health problem in Iran.

scholarly journals The Role of Endoglin in Hepatocellular Carcinoma

2021 ◽  
Vol 22 (6) ◽  
pp. 3208
Author(s):  
Kuo-Shyang Jeng ◽  
I-Shyan Sheen ◽  
Shu-Sheng Lin ◽  
Chuen-Miin Leu ◽  
Chiung-Fang Chang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Diseases ◽  
Transforming Growth Factor ◽  
Antiangiogenic Therapy ◽  
Transforming Growth Factor Β ◽  
Postoperative Recurrence ◽  
Transmembrane Glycoprotein ◽  
Early Progression

Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.

Sign in / Sign up

Export Citation Format

Share Document